AstraZeneca PLC · LSE:AZN
AstraZeneca — H1 2003 Earnings Presentation
14 slides from AstraZeneca's earnings presentation, Jul 24, 2003
Slide 1: A General Presentation: Half Year results 24 July 03
A General Presentation Half Year results 24 July 03 1 HY 2003 Headline results HY 03 HY 02 CER $m $m growth Sales 9,171 8,658 - Operating profit 2,161 2,361 -10% EPS $0.93 $1.00 -8% Share repurchase 311 748 2 A A
Slide 2: Q2 2003 Headline results and Summary
Q2 2003 Headline results 2Q 03 2Q 02 CER $m $m growth Sales 4,436 4,312 -4% Operating profit 889 1,064 -18% EPS $0.39 $0.45 -16% Share repurchase 182 608 3 A Summary b Strong first half performance – Sales unchanged (CER) in spite of loss of $1.2bn in US Prilosec®, Zestril® and Nolvadex® sales b Fir
Slide 3: Portfolio transformation
Portfolio transformation Exanta™ Crestor® 2001 2003 Iressa® Prilosec® Faslodex® Zestril® Symbicort® Nolvadex® Nexium® Plendil® Casodex® Arimidex® Zomig® Seroquel® Atacand® 5 A Current portfolio 2001 Prilosec® b Drive Zestril® growth Base Mature Nolvadex® products Plendil® b New launches Growers 6 A
Slide 4: Drive the Growth Products
Drive the Growth Products Moving annual totals 4,000 3,500 3,000 2,500 $m 2,000 1,500 1,000 500 0 Q2 00 Q2 01 Q2 02 Q2 03 7 A Seroquel® Casodex® Atacand® Zomig® Arimidex® Seroquel®: US NRx in anti-psychotic market Market share 35% 30% Risperdal® 25% Zyprexa® Seroquel® 20% 15% 10% 5% Abilify® Geodon®
Slide 5: Seroquel - opportunity in mania
Seroquel® - opportunity in mania b Bipolar disorder constitutes estimated multi-billion dollar market b sNDA submission for treatment of acute mania associated with bipolar disorder on 2 January 2003 b Submitted for EU approval 7 February 2003 9 A Arimidex® performance Sales $m 400 350 Arimidex® 300
Slide 6: Casodex performance
Casodex® performance Sales $m 800 700 Casodex® 600 500 400 300 200 100 flutamide cyproterone nilutamide 0 Q2/98 Q3/98 Q4/98 Q1/99 Q2/99 Q3/99 Q4/99 Q1/00 Q2/00 Q3/00 Q4/00 Q1/01 Q2/01 Q3/01 Q4/01 Q1/02 Q2/02 Q3/02 Q4/02 Q1/03 11 Source: IMS Health MIDAS. Rolling MAT's. Sales in Actual USD. 32 countr
Slide 7: Total Prescription Market Share (PPI)
US PPI TRx market share 60% Total Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% 0 1 2 00 0 01 02 2 03 1 3 0 1 2 00 01 02 0 1 2 3 -0 -0 -0 -0 -0 -0 -0 l-0 l-0 l-0 -0 -0 -0 -0 n- n- n- n- p- p- p- ov ov ov ar ar ar ar ay ay ay ay Ju Ju Ju Ja Ja Ja Ja Se Se Se M M M M N N N M M M M Prilosec® N
Slide 8: PPI absolute US$ growth second to none
PPI absolute US$ growth ”second to none” A2B2 Acid Pump Inhibitors 15% C10A1 HMG-COA Reductase Inhibitors 10% N5A1 Atypical Antipsychotics 22% N3A Anti-Epileptics 19% B3C Erythropoietin products 15% N6A1 Anti-depressants 4% M1A3 Coxibs 5% R6A Antihistamines systemic 1% USD Growth Q1 03 MAT vs Q1 02
Slide 9: Symbicort and Iressa: breakthrough in lung cancer
Symbicort® $m 300 b COPD approved 250 in 16 countries 200 b Single Therapy 150 submission planned Q4 2003 100 b Phase III studies 50 underway in US 0 HY 01 HY 02 HY03 17 A Iressa®: A genuine breakthrough in the treatment of lung cancer b Iressa® specifically targets EGFR pathway and produces durable
Slide 10: Iressa - NSCLC and Crestor
Iressa® - NSCLC b Q2 03 sales $47m; HY 03 sales $66m b US - launch mid-May 03 – Q2 03 sales $18m – Through June, 5000 Rx dispensed* b Australia - approval 1st May 03 b Europe - monotherapy submission 11th Feb 03 19 *Source: IMS Health National Prescription Audit 2003 A Crestor® b Q2 03 sales - $9m,
Slide 11: Crestor data: STELLAR vs other statins
Crestor® data b Significantly greater reduction in LDL-C levels vs. Lipitor® across the dose range b Significantly greater increases in HDL-C levels b Crestor® 10mg gets significantly more patients to European LDL-C goal than atorvastatin 10mg (82% vs. 51%) b Data presented at ACC March 03 – Efficac
Slide 12: Exanta regulatory filings
Exanta™ regulatory filings b First filing for Exanta™ 24 July 02 in Europe – first indication for prevention of VTE in Orthopaedic surgery b New filings – USA – AF and Orthopaedic surgery 4Q03 – Europe – AF and VTE treatment 4Q03 23 A Exanta™ - publication summary b Trials presented to date – Europe
Slide 13: Exanta benefit risk profile
Exanta™ benefit risk profile b Thrombosis is the most common cause of death in the Western world b Current treatment has significant drawbacks – high unmet need b Exanta™ has efficacy and encouraging bleeding profile – Fixed dosing – No coagulation monitoring b Raised liver enzymes b Benefit-risk ev
Slide 14: Portfolio transformation and Cautionary Statement
Portfolio transformation Exanta™ b Absorb generic erosion Crestor® b Fund the launch programme Iressa® Faslodex® b 2003 EPS range increased Symbicort® to $1.65 - $1.75 Nexium® b Interim dividend increased Casodex® to $0.255 Arimidex® Zomig® b Strong sales and earnings Seroquel® growth from 2004 Atac